EGFR and non-small cell lung carcinoma: In recent years, the clinical application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the targeted therapy of patients with non-small-cell lung cancer (NSCLC) has been fully recognized.